Kornimate/medical-research-clean huggingface dataset:
recipients with limited bimodal benefit: ha or cros

Conditions: Cochlear Implant; Hearing Disability; Hearing Disorders and Deafness

Summary: the rationale is to determine (in individuals with limited perceived bimodal benefit) whether the cros device may be a better solution for obtaining two-sided input. if yes, this study would be practice-changing.

it is well accepted that bilateral input can significantly improve speech understanding in noise for patients with cochlear implants. for cochlear implant (ci) recipients who have a ci on only one side, two sided input can be provided with simultaneous use of a hearing aid (ha) or a cros device on the opposite side. the decision about which device to use depends on the level of residual hearing a recipient has in non ci-implanted ear, and more specifically what level of useable residual hearing s/he has. access to useable low frequency hearing can not only improve speech understanding in noise, it can also improve sound quality, pitch perception and music perception. clinicians can reasonably predict that a recipient with hearing thresholds better than 60 db hl at low frequencies (below 750 hz) would benefit from amplification. for recipients with no measurable acoustic hearing in the contralateral ear, cros would be a reasonable option, especially if bilateral implantation is not feasible or desired. however, it is more difficult to predict the appropriate device in individuals who have some measurable acoustic hearing but may be receiving limited benefit from it. this can be especially challenging because audiometric thresholds are not a reliable predictor of bimodal benefit. additionally, acoustic hearing can provide subjective benefits which could hold different intrinsic value or significance for different individuals depending on their life style and listening needs.

Eligibility criteria:
inclusion criteria: * adults (\> 18 years of age) * unilaterally implanted with an advanced bionics implant (cii or later) * at least six months of ci use * limited bimodal benefit as perceived by the recipient and/or the clinician * participants may or may not currently be using a hearing aid in the unimplanted ear. * open set performance with current device configuration: * ≥40% azbio sentence score in quiet (s0) and? (i.e. do both these apply) if currently bimodal: * hearing aid ear only cnc score \<50% * azbio scores bimodal benefit \<15% increase in score compared to ci only? * unaided audiometric threshold of ≤100 dbhl up to 500 hz * ability and willingness to participate in multiple sets of open speech testing (and ongoing evaluation of ha and cros benefit) exclusion criteria: * patients who are not proficient in english as the azbio testing is available in english only. * patients with agenesis of the contralateral ear

Keywords: cochlear implant hearing aid cros device bimodal
the effects of traditional herbal dietary supplements on general fatigue and negative emotions of graduate students

Conditions: Fatigue

Summary: the goal of this randomized controlled trial is to determine the effect of traditional herbal supplements on general fatigue and negative emotions in generally healthy graduate students. the main questions it aims to answer are: • whether the traditional herbal supplements can ameliorate fatigue and negative emotions of young adults

participants will: * take oral herbal supplements or placebo as randomized for four weeks * be evaluated for the fatigue, anxiety, and depression levels at baseline and four weeks after the intervention * record sleep variables each day for five weeks researchers will compare the intervention group (receiving herbal supplements) with the placebo group (receiving placebo) to see if oral herbal supplements have effects on the outcomes and to examine the anti-fatigue effect two weeks after intervention.

Eligibility criteria:
inclusion criteria: * scoring at least 4 points on the dichotomous chalder's fatigue scale at baseline * working on at least one ongoing research project and expecting to continue working for at least one month exclusion criteria: * taking medications as: * antidepressants * anxiolytics * cns stimulants * immunosuppressants * with underlying diseases as: * diabetes mellitus * hematologic diseases * other major diseases as defined my mohw of taiwan

Keywords: astragalus traditional herb fatigue negative emotions graduate students young researchers
artificial intelligence-based computer-aided diagnosis of prostate cancer

Conditions: the Application of Artificial Intelligence in the Diagnosis of Prostate Cancer

Summary: one-fifth of all men will develop clinically significant prostate cancers (cspc) in their lifetime. an estimated 268,490 new prostate cancer (pca) cases and 34,500 deaths are expected in the united states during the year 2022, making pca the second most common cause of cancer-related deaths in men. mri with the prostate imaging reporting and data system (pi-rads) is a current widely used communicative tool for both cspc detection and guiding targeted prostate biopsy. the high level of expertise required for accurate interpretation and persistent inter-reader variability has limited consistency and it has hindered the widespread adoption of pi-rads. artificial intelligence (ai) shows a broad prospect for medical interpretation and triage in various challenging tasks , including the pca detection and staging with mri. while rapid technical advances are furthering the application of ai medical imaging, their implementation in clinical practice remains a major hurdle. besides, the prospect of data-derived ai tool is to assist human experts rather than replace them, and whether ai can match or exceed the human experts is still a matter of debate. therefore, despite strong potential, there is urgent need for research to better quantify the accuracy, generalizability and clinical applicability before the clinical use of an ai in a real-world clinical setting.


Eligibility criteria:
inclusion criteria: * clinical suspicious of prostate cancer, presenting with an elevated prostatic specific antigen and/or abnormal digital rectal examination exclusion criteria: * (1) \<60 years of age; (2) a previous surgery, radiotherapy or drug therapy for prostate cancer (interventions for benign prostatic hyperplasia or bladder outflow obstruction were deemed acceptable); (3) incomplete mp-mri examination or artifacts of the images.

Keywords: artificial intelligence prostate cancer magnetic resonance imaging
predictor for an additional benefit of inhaled corticosteroid in patients treated with tiotropium for copd

Conditions: COPD

Summary: study purpose is to evaluate if subjects with chronic obstructive pulmonary disease (copd) are more likely to be responsive to additional inhaled corticosteroids if they have a positive response to hyperosmolar challenge with mannitol than if their response is negative.

in patients with chronic obstructive pulmonary disease (copd), the treatment with inhaled corticosteroids (ics) is controversial. preliminary results of our recent pilot study in 30 copd patients showed for the first time, that ics response mey be predicted by a bronchoprovocation challenge test with mannitol. however, this finding needs to be proven in a placebo-controlled trial. for this cohort study, 100 corticosteroid-naive, non reversible (fev1) patients with copd will be recruited. spirometry before and after bronchodilation will be measured at study entry and at four weeks run-in (only tiotropium) and at three month of treatment with tiotropium and ics or placebo. quality of life (st. george respiratory quality of life questionnaire) and exacerbation rate of copd will be assessed. measurement of exhaled nitric oxide and mannitol challenge will be performed at study entry and at 1 and 4 month. primary endpoint will be improvement in fev1 in each group (positive and negative mannitol challenge) after 3 months follow up. secondary endpoints will be the difference in dose-response-curve in the mannitol challenge, exacerbation rate and change in quality of life after three month follow-up.

Eligibility criteria:
inclusion criteria: * fev1/fvc \< 70% * fev1 % predicted \> 60% exclusion criteria: * other major disease * asthma * currently taking inhaled corticosteroids * oral corticosteroids in the last 3 month * significant cardiovascular disease * pregnancy/breast feeding * current use of salmeterol or other long acting bronchodilator

Keywords: inhaled corticosteroids copd mannitol
exercise to boost response to checkpoint blockade immunotherapy

Conditions: Cutaneous Melanoma; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma

Summary: 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles


Eligibility criteria:
* inclusion criteria: * age ≥ 18 years * able to read and speak english fluently * capable of giving informed consent * reported ability to complete 20-30 minutes moderate exercise per positive response to "can you currently walk unaided for six minutes or more?". * scheduled for first-time checkpoint blockade immunotherapy with fda-approved drugs, including avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab in the absence of other therapies (e.g. targeted therapy) * melanoma patients (adjuvant setting) * melanoma patients (neoadjuvant setting) * cuscc patients (neoadjuvant setting) * merkel cell carcinoma patients (neoadjuvant setting) participants may also be required to have a full covid vaccination series; the most up-to-date best practice guidelines for research at moffitt cancer center will dictate the need for such a vaccination series. exclusion criteria: * presence of medical conditions, such as severe cardiovascular disease for which an exercise intervention may not be warranted. * presence of major postoperative complications for which an exercise intervention may not be warranted.

Keywords: exercise checkpoint blockade immunotherapy immunotherapy skin cancer
benzodiazepines for the reduction of distress and pain during and after emergency department care

Conditions: Acute Pain

Summary: in this proposal, the investigators will determine if a single dose of oral lorazepam reduces distress, pain severity, and need for opiate analgesics both in the ed and in the acute recovery period after discharge. the investigators will compare the lorazepam arm to a placebo arm.

the investigators will enroll 120 medically stable adult patients who present to two emergency departments with a physical injury (\< 24 hours ago) and a chief complaint of pain. the investigators will randomly assign subjects using a blocked randomization schedule to either: 1) a single dose of oral lorazepam (1mg), or 2) oral placebo. emergency department providers and patients will be blind to treatment allocation. all participants will complete measures of negative affect and pain scores at baseline, and and 1 and 2 hours post-study drug administration. the investigators will record any analgesics administered in the emergency department until discharge. patients will also undergo quantitative sensory testing in the emergency department at baseline, and after study drug administration. at 14-days post-discharge, the investigators will measure summary reports of pain, mood, and analgesic medication used.

Eligibility criteria:
inclusion criteria: * adults between the ages of 18-65 * sustained a physical injury with a pain score ≥ 5 on the numeric rating scale \[nrs\] from 0- 10 with anchors of 0 = "no pain" and 10 = "worst pain imaginable" * expected to be in the ed for at least 2 hours, in a private treatment room * ownership of a cell phone with text messaging capabilities * emergency department admission assessment confirmed subject is not suicidal. exclusion criteria: * non-english speaking * not medically suitable for lorazepam per treating md (e.g. medical condition where benzodiazepines are contraindicated or may be unsafe) * not alert and oriented * active psychosis, self-injury, suicidal/homicidal intentions on initial evaluation by treating team * seeking treatment due to a mental health or substance use disorder * history of chronic opioid use * prescribed opioid or benzodiazepine use within the past 24 hours * alcohol use within the past 12 hours or medical history of alcoholism. * clinical indication for open-label benzodiazepine administration in the ed. * any use of recreational narcotics throughout lifetime * sensitivity or allergy or intolerance to opioids or benzodiazepines * current neurological disease (e.g., multiple sclerosis, stroke, brain tumor, seizure disorder, etc.) * prisoner
effect of educational intervention in mothers for prevention of caries in their children

Conditions: Dental Caries

Summary: the purpose of this study is to determine the effect of an educational intervention on mothers knowledge, attitudes and practices for preventing childhood caries.

health education is being used as a key preventive tool in the prevention of chronic diseases such as heart disease, cancer, obesity, mental illness, neurological disturbances as well as dental diseases. amongst the dental diseases, dental caries is a high prevalence chronic childhood disease having long term growth and developmental implications . a number of educational programs have been utilized to decrease its prevalence especially in disadvantaged communities. dental caries is a complex interplay of a number of risk factors such as demographic (socioeconomic status, race, etc.) behavioral, dietary and cultural factors. among the dietary intake, the most significant risk factor has been a high frequency intake of sugary foods and drinks.patterns of sugar intake are established early in life and sugar intake increases in the first two years of life. early feeding practices and lack of oral hygiene maintenance have been identified as risk factors for caries in subsequent years. maternal education can prove to be protective against dental caries by way of child's dietary practices. research has also indicated a reduction in prevalence of caries in children whose parents were previously participants of an oral health educational program. educating mothers about oral hygiene and feeding practices before the child transitions from exclusive milk diet to a variety of foods in an important time to exert a positive influence on dietary intake of child and overall oral health.

Eligibility criteria:
inclusion criteria: * mothers of 9-15 months old attending the vaccination clinic who consented to be a part of the study exclusion criteria: * mothers with severely ill children or children suffering from a co-morbid disease.
distalization via skeletally-anchored distaljet appliance with two approaches of micro-osteoperforations

Conditions: Class II Division 1 Malocclusion

Summary: study will be directed to evaluate two approaches of micro-osteoperforations during maxillary molar distalization.

maxillary molar distalization via skeletally anchored distal jet appliance randomly divided into two equal groups

Eligibility criteria:
inclusion criteria: * inclusion criteria: all patients should satisfy the following criteria:- 1. age range from 13-17 years. 2. bilateral class ii molar relationship. 3. skeletal class i or mild class ii relationship. 4. normodivergent skeletal pattern 5. no posterior crowding or diastemas. 6. fully erupted maxillary first and second molars. 7. congenitally missing or extracted third molars. 8. good oral and general health. 9. no systemic disease/medication that could interfere with otm. 10. no previous orthodontic treatment. exclusion criteria: * exclusion criteria: 1. patient diagnosed to have an indication for non-extraction approach. 2. poor oral hygiene or periodontally compromised patient. 3. patient with craniofacial anomalies or previous history of trauma, bruxism or parafunctions. 4. previous orthodontic treatment
prevention of atherosclerosis and heart disease in patients with systemic lupus erythematosis (sle)

Conditions: Systemic Lupus Erythematosus; Lupus

Summary: the purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or sle). the study will evaluate the effectiveness of medication and a phone-based education program in controlling four risk factors for heart disease: smoking, obesity, high blood pressure, and inactivity. the study will also test the safety of commonly used heart medications in people with lupus.

people with sle are at much higher risk for mortality due to atherosclerotic vascular disease (asvd). available data suggest that the usual mechanics of and risk factors for atherosclerosis are enhanced by factors such as corticosteroid use and sle itself. this study will evaluate a medication and education program designed to prevent asvd complications (primary prevention) or their recurrence (secondary prevention). the study will also measure the compliance and retention rate for the prevention program over 4 years. participants in this study will be randomized to receive either preventive heart disease medications or placebo. participants in the medication arm will receive pravastatin alone or in combination with the following: aspirin, ramipril, or a combination of vitamins b6, b12, and folate. all participants in this study will receive basic education on how to optimize their heart health. educational material will be sent to the patients as well as to support persons whom they have named. one group will receive tailored education based on a particular risk factor. participants will have three study visits and follow-up telephone visits four times a year. study visits will include a medical history and basic laboratory blood tests. participants with documented high blood pressure will receive a home monitoring unit and be asked to monitor their blood pressure. participants will be followed for 2 to 4 years.

Eligibility criteria:
inclusion criteria * sle as defined by the 1997 american college of rheumatology criteria * acceptable methods of contraception exclusion criteria * participation in another experimental protocol for asvd prevention * heavy alcohol consumption ( \>= 3 drinks/day) * aspirin intolerance * certain medications, including coumadin, ace inhibitors, potassium supplements, potassium sparing diuretics, cyclosporine, and lithium * peptic ulcer disease within 6 months prior to study entry * history of an intracranial bleed or brain tumor * bleeding diathesis * history of allergy or sensitivity to ace inhibitors * uncontrolled high blood pressure (180 mm hg/110 mm hg) * creatinine \> 2.0 mg/dl * renal artery stenosis * pregnant or breastfeeding * abnormal liver function tests (alt \> 2 x upper limit of normal) * history of a muscle disease, or baseline cpk \> 500u/l or 2 x upper limit of normal

Keywords: sle accelerated atherosclerosis cholesterol
the inspire bio-resource research platform for healthy aging inspire platform

Conditions: Biological Aging

Summary: since aging is a systemic (not organ-specific) phenomenon, the main objective of inspire bio-resource research platform for healthy aging is to build a comprehensive research platform gathering biological, clinical (including imaging) and digital resources that will be explored to identify robust (set of) markers of aging, age-related diseases and ic evolution. the inspire platform will gather data and biospecimens from subjects of different ages (from 30 years or over - no upper limit for age) and functional capacity levels (from robust to frail to disabled) over 10 years.

this is a 10-year observational study. the study will be performed in occitania region. once a year, a complete data collection will be performed in the gerontopole of toulouse, in participants' home and health centers by the gerontopole mobile research team, and in selected gerontopole's collaborating centers in occitania. between yearly waves of data collection, participants will have their intrinsic capacity domains monitored (with or without the help of a caregiver) each 4-month through the use of either an app developed in collaboration with world health organization (who) or a web platform; or through a phone call by a clinical/research nurse. for the first self-monitoring of ic at four months, all participants will be contacted by a research/clinical nurse by phone; this call will inform about how participants measured their capacity and/or help them to do it. after this first 4-month phone call, participants capable of correctly self-monitoring their ic through the app will no longer be systematically contacted by phone. once ic declines are confirmed, participants will have a thorough clinical assessment and blood sampling; such information will allow us to investigate the response of markers of aging at the time declines are detected. those needing usual care, will be followed according to who framework recommendations proposed for integrated care for older adults (icope).

Eligibility criteria:
inclusion criteria: * aged 30 years-old or over; * both sexes * affiliated to a social security scheme exclusion criteria: * severe disease compromising life expectancy at 5 years; * deprived of their liberty by administrative or judicial decision, or under guardianship

Keywords: geroscience biological aging and identifying targetable biomarkers the inspire bio-resource research platform for healthy aging aged 30 years-old or over age-related chronic diseases